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ABSTRACT 
 
Full Name : Khalid Hamid Omer Mohamed 
Thesis Title : Interaction studies of some potential anticancer Gold(III) complexes of 
1,2-diamine containing ligands with  some Biomolecules 
Major Field : Chemistry 
Date of Degree : May 2015 
The interaction of gold(III) diammine complexes [Au(en)Cl2]Cl, [Au(en)2]Cl3, [Au(cis-
DACH)Cl2]Cl and [Au(cis-DACH)2]Cl3 with biologically important  molecules like 
Glutathione (GSH), DL-Penicillamine (PSH), Mercaptoacetic acid (MAA) and N-(2-
mercaptopropionyl)glycine (MPG), L-methionine (Met), L-selenomethionine (SeMet), 
imidazole (Imi), Thiomalic acid (TmSH) have been studied spectroscopically and 
electrochemically in aqueous solutions. The NMR data show oxidation of thiols to its 
disulfide (RSSR) along with reduction of gold(III) to gold(I). UV-Vis Kinetic scan shows 
formation of intermediates with formulas [Au(diammine)(SR)X]+ (X: Cl in mono-
complexes, N in bis-complexes) at about  231 nm   and [Au(diammine)(SR)2]
+ at 297 nm 
which are not observable in NMR. The pseudo-first order rate constants and activation 
parameters (∆Hǂ, ∆Sǂ and Ea) were determined using UV-Vis spectrophotometeric data. 
The kinetics data for reaction with GSH indicates that the reactivity of ethylenediammine 
gold(III) complexes is higher than that for 1,2-diamminocyclohexane gold(III) complexes. 
The  reactivity towards substitution reaction is found to be [Au(en)Cl2]
+ > [Au(en)2]
3+ > 
[Au(cis-DACH)Cl2]
+ > [Au(cis-DACH)2]
3+ while the reactivity of investigated thiols 
varied  with thiol size; viz MAA >> MPG > PSH > GSH. The [Au(en)Cl2]Cl gave a well 
defined (SWSV) signal at + 0.875V (vs Ag/AgCl sat KCl ). Subsequent addition of 50 μM  
GSH to gold complex reduced the obtained complex signal with appearance of  a new 
signal around +1.4V. 
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 ملخص الرسالة
 خالد حامد عمر محمد : الاسم الكامل
 
ن ثنائى الامي -1,2المشتقة من ليكاندات  3دراسة تفاعلات بعض معقدات الذهب + : عنوان الرسالة
  بعض الجزيئات الحيويةالمحتملة كمضادات للسرطان مع 
  علوم الكيمياء : التخصص
 
  5102 يوما :تاريخ الدرجة العلمية
المحضرة احادى وثنائى ايثيلين داى امين وسيس داى امين سيكلو هكسان  3+تفاعلات معقدات الذهب 
لبنسيليامين , الثيوماليك اسيد , الميركابتو مع الجلوتاثيون , المثيونين , السلينومثيونين , الاميدازول , ا
استيك اسيد والميركابتو بروبينيل جليسين  قد درست فى محاليلها المائية باستخدام الاجهزة الطيفية 
الرنين النووى المغناطيسى والاشعة فوق البنفسجية والمرئية . الازاحة فى مقدار الازاحة الكيميائية دلت 
+ الى داى سلفايدات وسلفوكسيدات بينما تم اختزال 3ثيو ايثر بواسطة الذهبعلى اكسدة الثيولات وال
+ . الطيف الالكترونى لمحلول التفاعل دلل على تكون مركب وسيط متوقع ان 1+  الى الذهب 3الذهب
 792+ مع المرتبطة داى امين سايكلو هكسان وجزيئين من الثيول عند طول موجى 3يكون للذهب 
لم يتم ملاحظة هذا المركب الوسيط باستخدام الرنين النووى المغناطيسى . عوامل نانوميتر فى حين 
التنشيط لهذة التفاعلات(ثابت المعدل, انثالبى التنشيط ,انتروبى التنشيط و طاقة التنشيط) تم حسابها تحت 
التفاعل مع ظروف الرتبة الاولى غير الحقيقة  باستخدام اجهزة الاشعة فوق البنفسجية والمرئية نتائج 
الجلوتاثيون دلت على ان الفاعلية تترتب وفقا للاتى: معقد احادى اثيلين ثنائى الامين> معقد ثنائى اثيلين 
ثنائى الامين > معقد احادى داي امين سيكلو هكسين > معقد ثنائى داي امين سيكلو هكسين   بينما فعالية 
يد >> الميركابتو بروبينيل جليسين > البنسيليامين الليكاندات وجدت تتبع الترتيب: الميركابتو اسيتك اس
> الجلوتاثيون. المركب احادى ايثيلين داى امين اعطى قمة واضحة على باستخدام تقنية الاسكوير ويف 
ملى مولار ضد الكترود الفضة/ كلوريد الفضة فى محلول  1فولت لمحلول بتركيز  578.0عند قيمة +
ميكرو مولر من محلول الجلوتاثيون ادت الى  05ضافة المتتابعة ل كلوريد البوتاسيوم المشبع , الا
 فولت .  4.1+فولت مع ظهور قمة جديدة عند حوالى  578.0اختزال القمة المعطاه للمعقد عند +
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CHAPTER 1 
1 INTRODUCTION 
1.1 Metallodrugs in cancer treatment:  
The emergence  of cisplatin during the 1960s as a powerful anticancer agent excited a 
considerable deal of solicitude in the field of anti-tumour metallodrugs [1]. Although 
cisplatin has been used for decades in human cancer treatment, some resistance and toxic 
side effects were reported [2]. After a great success of cisplatin in cancer chemotherapy  
especial attention had been paid to gold(III) complexes due to the similarity between 
gold(III) complexes and cisplatin, both are isoelectric d8 electronic system and 
isostructural and their complexes are tetracoordinate in centre of square planar [3]. One 
of the most important concerns of recent bio-metallic and bio-inorganic chemistry is to 
develop and introduce new metal based drugs [4–13]. The use of gold in anti-rheumatic 
treatment supports its pharmaceutical importance [14–17]. However gold(III) complexes 
are not stable enough under physiological conditions due to their high reduction 
potentials and fast rate of hydrolysis recently  many gold(III) complexes were found to be 
unstable under physiological conditions and that was achieved by using property of 
interaction of gold(III) with biological ligands such as amino acids and peptides which 
are well known good chelating ligands that are able to bind with various metal ions [18], 
so the ligand selection is a very significant factor to improve the stability of gold(III) 
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complexes against hydrolysis and reduction and thus provide gold(III) complexes that are 
appropriate for biomedical applications [19]. Moreover the design of an efficient 
anticancer agents is very sophisticated game that encompass beside its inherent inhibitory 
action the resident time in vivo, dosage and delivery [20]. Because of high reduction 
potential of gold(III) complexes, it can be easily reduced to gold(I) or gold(0), and this is 
a conceivable problem in the body due to the existence of reducing thiol moieties, e.g 
amino acid cysteine (HSCH2CH(NH2)CO2H). However, in recent years, an enormous 
number of gold(III) complexes with low reduction potentials for central metal ion were 
introduced; that success was achieved by utilizing  polydentate ligands and it showed 
tangible stability under physiological conditions,  this  manifest very promising antitumor 
activity against different human tumor cell lines, both in vitro and in vivo [21].                                       
To overcome the instability against hydrolysis, reduction reactions and to introduce 
gold(III) complexes suitable for biomedical applications, suitable ligands must be 
selected [19]. The possible involvement of gold(III) complexes in cancer treatment 
initiated an interest in the interactions of Au(III) with different bioligands, such as 
peptides and proteins. The most important amino acid in the study of interactions of 
metal ions with peptides and proteins is L-histidine, since it is found in the active sites of 
several metalloenzymes and of metal transport proteins [3].  
1.2 Aim of study: 
Recently, a great attention has been focused on the analysis of the interactions of 
cytotoxic gold (III) porphyrins with DNA. The first mechanistic studies on gold(III) 
porphyrins (using gold(III) mesotetraarylporphyrins) shows that they interact strongly 
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and directly with DNA, implying that DNA may actually constitute a preferential 
biomolecular target. However, in a successive study, the same authors reveal that 
gold(III) porphyrin  acts differently from cisplatin in vivo as the gold compound causes 
DNA fragmentation rather than cross-linking; moreover, its interactions with DNA are 
reported to be noncovalent and reversible in nature [22]. Therefore the stability of 
gold(III) complexes toward the substitution reaction with some important biological 
target ligands such as protein, DNA, RNA and amino acids (especially sulfur containing 
amino acid) is consider  an interesting area for research.  
1.3 Technique and Methodology:  
Preparation of gold(III)  complexes is performed by a general method described in 
literature [23] for similar compounds by mixing gold(III) salt solution with each ligand 
solution. These complexes were characterized using elemental analysis, thermal analysis, 
mid- and far-IR spectroscopy, and NMR (1H and 13C) spectroscopy. Interactions of 
prepared gold(III) complexes with targeted bioligands studied using NMR by monitoring 
the change in chemical shifts for 1H, 13C and 15N in the reaction mixture. The Kinetic 
studies of these interactions will be studied by employing UV-Vis spectrometry after 
investigating working wavelength and pH under pseudo first order condition as a function 
in ligand concentration. Rate of reaction and activation parameters will be calculated. 
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1.4 Research Objectives:  
1. Interactions of the following complexes, [cis-1,2-(DACH)AuCl2]Cl, [Au(en)Cl2]Cl 
with Glutathione, Thiomalic acid, DL-Penicillamine will be studied by 13C NMR. 
 
2. Interactions of the following complexes [cis-1,2-(DACH)2Au]Cl3 and [Au(en)2]Cl3 
with Glutathione, Thiomalic acid, DL-Penicillamine will be studied by 13C NMR. 
 
3. Interactions of the following complexes, [cis-1,2-(DACH)AuCl2]Cl, [Au(en)Cl2]Cl 
with R–S-CH3-L-Methionine, R–Se-CH3-(DL-Seleno-Methionine) will be studied 
by 13C NMR. 
 
4. Interactions of the following complexes [cis-1,2-(DACH)2Au]Cl3, and [Au(en)2]Cl3 
with L-Methionine, DL-Seleno-Methionine) will be studied by 13C NMR.  
 
5. Interactions of the following complexes, [cis-1,2-(DACH)AuCl2]Cl, [Au(en)Cl2]Cl 
with Imidazole, Guanine and Cytosine will be studied using  13C and 15N NMR in 
solution. 
 
6. Interactions of the following complexes [cis-1,2-(DACH)2Au]Cl3, and [Au(en)2]Cl3 
with Imidazole, Guanine and Cytosine will be studied using  13C and 15N NMR in 
solution 
 
7. The kinetics of these interactions will be studied using UV-Vis spectrometry and 
activation parameters for these interactions will also be calculated.   
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Cisplatin and its anticancer activity:  
Cisplatin is a powerful anticancer agent that was discovered by Rosenberg and his 
coworkers during an experiment using platinum electrodes to study the effect of electric 
fields on the growth of bacteria (E. coli); later this active compound was investigated and 
this chance observation led to such a powerful antitumor drug which is described as a 
tetra coordinate  platinum(II) in the centre of square planar  coordinated to two chloride 
ligands and two ammonia ligands with cis conformation and it is known by cisplatin, its 
chemical structure  is illustrated in Figure 2.1 [6]. 
 The possible mechanism of cytotoxicity of cisplatin might be through drug’s interaction 
with DNA. Since the cisplatin is injected  into the bloodstream and is believed to exist  in 
its neutral state until after it crosses the cell membrane where one or both chlorides are 
displaced by aqua ligands (the chloride concentration being lower inside than outside the 
cell) affording cationic compounds. These cationic aqua derivatives react with the bases 
on DNA, most commonly with the N7 of purine bases (with guanine favored over 
adenine) which displace the aqua/chlorido ligands. A bifunctional adduct is formed 
between the {cis-Pt(NH3)2} unit and two adjacent bases on the same strand (the 1,2 
intrastrand GG adduct accounts for >70 % of all adducts formed: 1,2 intrastrand AG 
adducts are the next most common at around 20 % of all lesions: 1,3 adducts and 
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monoadducts are much less common). The platinum center is located in the DNA major 
groove, and the effect of the platinum coordination to two adjacent bases is to bend (kink) 
the DNA by around 45°, toward the site of platination this bent DNA structure is then 
recognized by nuclear high-mobility group (HMG) proteins which bind and are believed 
to protect the lesion from DNA repair [24].  
 
 
 
 
Figure2.1: Cis-diamminedichloridoPlatinum(II) 
2.2 Gold complexes as anticancer agents: 
Although cisplatin has been used for decades to treat human cancer, some toxic side 
effects and resistance are observed [8]. neurotoxicity, ototoxicity, anemia, nephrotoxicity 
and nausea (vomiting) are some of cisplatin side effects observed [9]. After success of 
cisplatin great interest had been paid to Au(III) complexes as new candidates for cancer 
treatment because Au(III) complexes  are  isoelectrical and isostructural with platinum(II) 
complexes; both are d8 electronic systems and coordinate to four ligands in center of 
square planar geometry [2].  
The emergence of Au(I) and Au(III) complexes overcome some of these challenges by 
forming strong covalent attachments to targets and added advantage of decreased toxicity 
[2]. 
Pt
NH3Cl
NH3Cl
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Au(I) is d10 electronic system and complexes containing Au(I) found linear with two 
coordinate, the most important Au(I) complexes that has been used for medicinal 
purposes are thiolate and phosphene complexes, like auranofin, aurothiomalate, 
aurothioglucose, and auro-bis(thiosulfate), this preference of thiols and phosphines can 
referred to Au(I) is soft cation prefers binding with soft ligands [22]. 
 Due to high potential of reduction and fast rate of hydrolysis Au(III) complexes were 
found to be unstable enough under physiological conditions like a Pt(II) complexes [25] 
but recently, a large number of gold(III) complexes were developed and the reduction 
potential of gold center was lowered by using polydentate ligands, that development was 
initiated by interactions properties of Au(III) with important biological molecules such as 
amino acids and peptides which are capable to coordinate many metal ions and form 
chelate of stable five member ring based on amino nitrogen and carboxylate oxygen. In 
peptides, this type of binding involves the nitrogen atom of amide bond(s) because the 
terminal amino nitrogen and carboxylate are too far from each other to coordinate to 
same metal ions [25].   
2.3 Gold(I) complexes: 
Gold(I) complexes are considered very interesting from applied and basic concern [26–
28]. These complexes exhibits unusual liking between Au….Au characteristic of this sort 
of interaction. These interactions are stronger than van der waals but weaker than 
ordinary covalent bonds, and they were first found in gold complexes because of that 
these phenomena known by aurophilic.  Gold complexes have been gaining significant 
role in medical field since they were used by ancient before more than 2000 years 
[29,30]. Today a number of gold based drugs are used to treat rheumatoid arthritis 
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symptoms, like aurothiomalate, aurothioglucose, aurothiosulfate, 
triethylphosphinegold(I)-tetraacetyl-thioglucose  and aurothiopropanol sulfonate and they 
are also used mainly to prevent destructive progress of disease and this type of drugs 
which are used as inflammatory agents called Disease Modifying Antirheumatic Drugs 
(DMARDs), and the Antirheumatic gold compounds classified as DMARDs [8,31]. 
In vitro studies on auranofin showed that it also exhibit promising cell growth inhibition 
effects and some effectiveness was reported with in vivo models and that is in 
relationship with administrated dose in inoculated mice [32]. Moreover limited efficiency 
obtained in others in vivo studies and the reason till now is unclear. It might be that 
auranofin is a competent antitumor candidate, while among all tested mouse tumour 
models it was reported active only against i.p. P388 [33]. These observation have directly 
initiated immense attention on gold complexes as anticancer agents. 
2.4 Gold(II) complexes: 
Three stable platinum complexes were synthesized and characterized in unusual 
oxidation state as Pt+3 with octahedral geometry based on hematoporphyrin ligands. 
These three complexes were obtained in different kind of coordinate to HP ligand since it 
is controlled by M:L ratio and Pt(II) precursor;  and the interaction of Pt(II) with HP 
leads to formation of Pt(III) accompanied with  organic radical and appreciable decrease 
in pH. Their anticancer activity was evaluated against human cancer cell lines, [Pt(III)HP-
2H.(H2O)2] shows promising  cytotoxicity towards tested cancer cell lines [34]. Stable 
monomeric gold(II) complexes with HP in alkaline solution was obtained and formula 
[Au(II)HP-2H. (H2O)2] was suggested for octahedral complex ( Figure 2.2); furthermore 
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+2 oxidation state for gold had been proven by EPR [35]. Prepared Au(II)-
hematoporphyrin was studied in a panel of cancer cell lines and it displays significant 
cytotoxicity; moreover high sensitivity noticed with lymphoma and leukemia cells with 
corresponding IC50 values even comparable to cisplatin [36]. 
N
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CH3
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Figure2. 1: [Au(II)-HP-2H.2H2O] 
 
 
2.5 Gold(III) complexes:  
Depending on their similarity to cisplatin in structure and electronic, gold(III) complexes 
can be considered as strong candidates to achieve promising anticancer activity. 
However, involvement of gold(III) complexes as therapeutic agents has been limited by 
their poor stability under physiological conditions. 
A number of gold(III) complexes were reported and their anticancer activity was 
investigated under physiological conditions, majority of them are gold(III) complexes 
containing Au-N and Au-Cl or Au-O bonds and some containing Au-C or Au-S bonds. 
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2.5.1 Gold(III) complexes containing Au-N bonds: 
Two gold(III) complexes with 2-subsituted pyridine having the following formulas  
[AuCl3(Hpm)] and [AuCl2(pm)] were obtained and their solutions disposal was studied in 
order to investigate their ability to act as anticancer agents. Fast release of bounded 
chlorides was observed in water with preserve gold(III) centre and heterocyclic five 
member chelating site moreover this hydrolysis is faster in a physiological buffer. Both 
gold(III) complexes react with protein leading to conversion of gold(III) to gold(I) that 
was observed with albumin and transferin, Moreover rapid and strong binding of 
gold(III) complexes to calf thymus DNA or polynucleotide was shown, and cytotoxicity 
studies prove good antitumor activity for both gold(III) complexes even comparable to 
cisplatin [37]. Some bipyridine (bipy) gold(III) complexes [Au(bipyc-H)(OH)][PF6] and 
[Au(bipy)(OH)2][PF6] were found to be stable at temperature 37ºC with physiological 
buffers, whereas, the cytotoxicity studied on calf thymus DNA showed that  interaction 
of tested complexes with DNA is reversible in nature and weak [38]. The use of 
polydentate ligands led to distinguish stabilization of gold metal centre in oxidation state 
of +3 under physiological-like conditions, and that can be clearly seen from their 
reduction potential measurements. [Au(en)Cl2], [Au(phen)Cl2]Cl, [AuCl(dien)]Cl2 and 
[Au(terpy)Cl]Cl2 exhibited good cytotoxicity in A2780 ovarian cancer cells. But 
[Au(cyclam)](ClO4)2Cl did not, moreover, the obtained results from cisplatin-resistance 
A2780 reflect the ability of these complexes to overcome drug resistance. The potency of  
free ligands was investigated and pointed out that the potency of free tripyridine and 
phenanthrene was similar to that for correspondening gold(III) complexes whereas free 
ethylenediamine driven ligands does not display any activity proving  the activity of their 
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gold(III) complexes is due to presence of gold(III) centre. The results from  
[Au(cyclam)](ClO4)2Cl indicates that increasing the stability of gold(III) is in reverse 
relationship with activity [39]. 
Compounds with similar structures were obtained for gold(III) using triazacyclononane 
ligand [Au(TACN)Cl2][AuCl4] and [Au(TACN)Cl2]Cl The structure of first complex was 
determined by XRD, circular dichroism spectroscopy, UV-Vis and fluorescence were 
employed to study the interaction of  [Au(TACN)Cl2]Cl with CT-DNA and the results 
shows that this complex can induce DNA double helix distortion that by replacing 
Ethidium bromide from DNA-EB system. Biological tests using A-549 and HCT-116 
tumor cell lines proved better activity than anticancer drug cisplatin [40]. Zhu et al 
synthesized gold(III)-ethylenediamine complexes and studied their interactions with 
GMP, the electrochemistry showed the formal negative potential of gold(III)/gold(0) 
increased in order [AuCl4]
-, [Au(en)Cl2]
+ then [Au(en)2]
3+ [41]. Furthermore, number of  
gold(III) complexes with alkylenediammine and N-alkyl-ethylenediamine  were prepared 
and tested against gastric, prostate and ovarian cancer cells [42]. [Au(en)Cl2]Cl produced 
minimum changes in liver and kidney, showing that it is safer than other therapeutic 
drugs [43]. [(sec-butyl)(phen)AuCl3] a penta-coordinate gold(III) complex, exhibits better 
cytotoxic properties compared with cisplatin itself [44]. The structure of some gold(III) 
containing Au-N bond is shown in figure 2.3 . 
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Figure2. 2: Some of gold (III) complexes containing Au-N bonds 
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2.5.2 Gold (III) complexes containing Au-S bonds: 
Gold(III) complexes with their Palladium(II) and Platinum(II) analogs with 
methylsarcosinedithiocarbamate (MSDT) were synthesized and characterized in order to 
study their ability to act as potential antitumor agents, [Au(MSDT)X2] gave significant 
activity compared with cisplatin as a reference  antitumor drug; and that in case of X is 
Cl or Br, [Au(MSDT)X2] induced apoptosis when it was exposed to HeLa cells and 
HL60 cells [45]. A superior gold(III) anticancer was obtained by coordinate to N,N-
dimethyldithiocarbmate (DMDT) and its in vitro results displayed cytotoxic behavior 
with value of IC50 value less than cisplatin by 1 to 4 times; also this activity extended to 
cisplatin sensitive cells that reinforce various mechanisms of action and  exclude cross-
resistance occurrence [46]. Gold(III) complexes with dithiocarbmate ligands gave full 
hydrolysis under physiological conditions  during first hour with preserving oxidation 
state for central metal as +3 in solution. An  in vitro study showed ability of examined 
complexes to bind to DNA leading to inhibition of formation of both DNA and RNA, and 
this can be rationalized by the high reactivity of gold(III) complexes towards some 
isolated biologically important macromolecules [47]. These compounds were found cause 
cancer cell death through apoptotic and non-apoptotic ways [48]. Recently, Isab and his 
coworkers  reported a new type mixed ligands gold(III) complexes with general formula 
[(thione)2Au(diamine)]Cl3 using different diamine and thione ligands [49]. Spectroscopic 
characterization of these complexes indicates that all thione ligands were bounded to 
gold(III) centre through their thiocarbonyl sites with square planear geometry, An in vitro 
study shows cytotoxicity comparable to cisplatin against C6 glioma cells. Structural 
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difference like ring size of diamine ligands and thione ligands might have affected in 
vitro activity of presented compounds.  
2.5.3 Gold (III) complexes containing Au-C bonds: 
Different gold(III) compounds containing one or more gold(III)-carbon bonds were 
evaluated against  TrxR and MCF-7 cancer cells. As gold(III)-carbon bonds were 
increased to two gold(III)-carbon bonds act as powerful inhibitors for reduction of Trx 
with IC50 value less than 2 nM. This inhibitory concentration does not correlate to ability 
of  killing cells, and only one complex with two gold(III)-carbon bonds (Figure 2.4) was 
found to inhibit the formation of colony by MCF-7 breast cancer cells at micromolar 
concentrations [50]. A group of gold(III) based on 2-phenylpyridine and some thiolate 
ligands shows better in vitro cytotoxicity than clinical cisplatin against both MOLT-4 
human leukemia and C2Cl2 mouse tumour cell lines [51]. Four gold(III) complexes with 
2-[(dimethylamino)methyl]phenyl (damp) ligands were tested in vitro and in vivo and  
results showed  good activity. Detailed studies on [Au(acetato)2(damp)]  showed that 
only minor cell cycle alterations occur and the compound did not cause DNA interstrand 
cross-linking [52]. The behavior of some gold(III)-carbon complexes was studied under 
physiological-like conditions to indicate that all compounds underwent hydrolysis for 
labile ligands were the gold(III)-carbon bonds and metal oxidation states were preserved 
[53,21]. 
 
 
 
Au
Cl
N
CH3
CH3
 Figure2. 4: Gold(III) complex with strong TrxR inhibitory properties 
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2.6  Interactions of gold(III) with Amino acids: 
 The mechanism of interaction for gold(III) with amino acids, peptides and proteins as 
well as structural characterization of intermediates formed in these reactions have been 
investigated and reported in detail. Examples of interaction with amino acids are 
discussed in this section. 
2.6.1 Interaction of gold(III) complexes with Glycine and Alanine: 
The  reactions between gold(III) complexes with amino acids Alanine and Glycine were 
successfully studied in acidic solutions at pH 2.90 and 2.44 respectively by using 
isotopically labeled amino acids and employing NMR techniques [54,55]. These 
reactions were carried out at room temperature using tetrachloridoaurate(III) [AuCl4]
− 
and  15N Gly in different molar ratios, and the reaction mixture was monitored by 1H 
NMR and 2D [1H, 15N] NMR in order to get more information about the reaction 
intermediate. The collected data showed that Glycine coordinates initially to gold(III) 
centre through its nitrogen atom forming intermediate product with formula [Cl3AuN-
gly] this intermediate can form chelation of five member ring by intramolecular 
substitution of second chlorido ligand to give [Cl2AuNO-gly]; On the other hand, two 
electrons transferred to gold(III) centre from amino acid lead to formation of gold(I)-
imine which is well known to be unstable and it hydrolyzes to release NH4
+ with its 
corresponding aldehyde. Further reaction with additional gold(III) complexes induced 
decarboxylation  of  glyoxylic acid to obtain formaldehyde concomitant with reduction of 
gold(I) to elemental gold(0) and formation of CO2 and this at 1:2 reactant ratios. All 
intermediates identified in this reaction according to its analogies platinum compounds 
chemical shifts values [54]. Similar behavior was observed with Alanine to give pyruvic 
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acid. Proposed mechanism for gold(III) reaction with both Glycine and Alanine in acidic 
solutions can be driven as first step coordinate of amino acides to gold(III) centre through 
their Nitrogen atoms followed by reduction of gold(III) to form gold(I)-imine complex 
then fast hydrolysis led to formation of glyoxylic acid and purovic acid  with concomitant 
formation of NH4
+ and Au(0), proposed mechanism is illustrated in (Figure 2.5). 
Moreover both Glyoxylic and pyruvic acid  can react with additional gold(III) complex 
giving formic and acetic acid, respectively, carbon dioxide and Au(0) [34,35]. 
2.6.2  Interaction of gold(III) complexes with L-Histidine:  
L-Histidine  is classified as the most important amino acid because it is part of the active 
site in many biological systems, such as enzymes [56]. The interaction of gold(III) with 
L-His have been studied utilizing a number of  instrumental techniques in order to 
determine the structure of product. The obtained results indicate that the binding of L-His 
to gold(III) centre and the coordination of L-His to gold(III) occur through amino group 
and N3 from imidazole ring, whereas, two molecules of L-His were coordinated to one 
gold(III) ion, [Au(L-His)2]Cl3 complex was slowly obtained after 3 hours as precipitate. 
This final product is concomitant with an increase in acidity of reaction solution owing to 
carboxyl group deprotonation [57]. Another study was for interaction of [AuCl4]
-  with L-
His amino acid in presence of perchloric acid. β-Imidazolyl-pyruvic acid was obtained as 
final product in this reaction, and  kinetic studies using UV-Vis spectrophotometry [58]. 
The interaction of [Au(en)Cl2]Cl with L-Histidine was found to be pH dependent and the 
oxidation of L-His by gold(III) complex was studied by monitoring 1H NMR chemical 
shifts. These studies showed fast gold(III) reduction to elemental gold(0) and L-His 
oxidation was observed in solution indicating preference of gold(III) binding to L-His, 
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hence the binding here is thought to be through amine group and N3 from imidazole ring 
and carboxyl group acts as counter ion. Under mentioned experimental conditions this 
reaction was reported as first order reaction [59]. 
2.3.3. Interaction of gold(III) complexes with sulfur containing amino acids: 
Although gold complexes have been used as drugs based in Chrysotherapy this, use was 
limited to gold(I) which were administrated in the form of thiolates e.g. gold(I) 
thioglucose which is used in rheumatoid arthritis. The interaction of gold complexes with 
sulfer plays very important role in gold biochemistry as gold(III) ability to oxidize thiols 
to disulfides and Methionine to Methionine sulfoxide are reported as a source of gold(III) 
toxicity [60]. 
An increasing attention in the gold(III) complexes interaction with sulfur-containing 
amino acids was observed after discovering antiarthritic properties of gold(I) thiolates, L-
Cysteine (L-Cys) is an important sulfur-containing amino acid and its interaction with 
gold(III) complexes was classified to be one of the reasons behind toxicity of gold(III) 
complexes for medical applications since it acts as a reducing agent reducing gold(III) to 
gold(I). L-Cys is also oxidized to generate disulfide products and cystic acid; further 
reduction of gold(III) complexes to elemental gold(0) occurs by cystic acid. These 
transformations are reported as toxic side effects in Chrysotherapy [60] such as 
nephrotoxicity. It was found that L-Cys is able to reduce gold(III) in aqueous solution. 
Cystine was found to be the major oxidation product in this reaction, with Au(III) being 
reduced to Au(I), which can be stabilized with excess L-cysteine. Disulfide cystine was 
capable of reducing Au(III) to elemental Au(0) while being itself oxidized to cysteic acid 
[25]. 
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The mechanistic study of the redox reaction between [AuCl4]
− and the amino acid L-
methionine was studied by UV-Vis spectrophotometry, thermal analysis, NMR, IR and 
FT-IR spectroscopy in acidic solution [61,62]. It was found that this reaction occurred in 
two stages. Initially, the very fast substitution of one chloride ion by L-Methionine 
molecule with formation of the short lived Au(III)–methionine complex was observed. 
Additionally, it was confirmed that the amino group of methionine was involved in this 
process even at pH below 2.00. The rate constant for the first stage of this reaction 
determined by applying a stopped-flow technique was found to be 983 ± 2 M−1 s−1 at 
21°C. The second stage of this reaction was reduction of the intermediate Au (III)–
methionine complex with formation of methionine sulfoxide and a Au(I) complex as the 
final products [62]. 
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Figure2. 3: Proposed mechanism of interaction of gold(III) complexes with amino acids. 
2.7 Interactions of Au(III) with Peptides: 
The reactions between two dipeptides, glycyl–glycine (Gly–Gly) and glycyl–L-alanine 
(Gly–L-Ala) and H[AuCl4] were studied at pH 2.00 and 3.00 at 40°C by 1H NMR 
spectroscopy. The final products in these reactions, [Au(Gly–Gly–N,N′,O)Cl] and 
[Au(Gly–L-Ala–N,N′,O)Cl] complexes, were identified and characterized by 1H and 13C 
NMR spectroscopy. From NMR data it was concluded that both dipeptides are tridentate 
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coordinated to Au(III) ion through the nitrogen atom of the terminal amino group, the 
deprotonated peptide nitrogen and the oxygen atom of the carboxyl group. The fourth 
coordination place in these square-planar complexes was occupied by the chloride ion. It 
was also stated that coordination of Gly–Gly and Gly–L-Ala dipeptides to Au(III) was a 
slow process strongly dependent on pH [3]. 
The redox reaction between glutathione (GSH, γ-L-Glu–L-Cys–Gly) and 
tetracyanidoaurate(III), [Au(CN)4]
− was investigated in aqueous solution at pH 7.4 by 
UV-Vis, 13C NMR and electrospray ionization mass spectroscopy (ESI-MS). It was 
found that the reduction of [Au(CN)4]
− by GSH proceeded through two intermediates, 
[Au(CN)3(GS)]
2− and [Au(CN)2(GS)2]
3−. These intermediate species further react with an 
additional molecule of GSH to generate [Au(CN)2]
− and glutathione disulfide (GSSG2−) 
as the final products of the reaction [63,64]. 
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CHAPTER 3 
Experimental work 
3.1 Synthesis of gold(III) complexes: 
3.1.1 Synthesis of [cis-1,2-(DACH)AuCl2]Cl: 
It was  prepared by direct mixing of one equivalent NaAuCl4.2H2O with one equivalent 
of diammine ligand in alcoholic media as per literature method [23]. 1H NMR:  δ ppm 
(density, multiplicity): 3.56(2, m), 2.14(2, m), 1.75(2, m), 1.50(2, m) and 1.32(2, m). 13C 
NMR as δ ppm: 63.35, 26.86 and 21.44ppm.  
3.1.2 Synthesis of [cis-1,2-(DACH)2Au]Cl3:  
It was  prepared by direct mixing of one equivalent NaAuCl4.2H2O with two equivalent 
diammine ligand in alcoholic media as per  literature[65], 1H NMR as δ ppm (density, 
multiplicity): 3.52(2, m), 1.87(2, m), 1.65(2, m), 1.50(2, m), 1.33(2, m). 13C NMR as δ 
ppm: 63.19, 62.92, 26.55, 26.10 and 20.82, 20.60 ppm. 
3.2 Solution NMR Measurements:  
All NMR measurements were made using a Jeol JNM-LA 500 NMR spectrophotometer. 
The 13C NMR resonance spectra were obtained with 1H broadband decoupling at a 
frequency of 125.65 MHz and they were referenced relative to TMS, the spectral 
conditions were 32 k data points, 0.963 s acquisition time, 1.00 s pulse delay and 45º 
pulse angle, The proton NMR spectra were obtained at a frequency of 500.00 MHz. 
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3.3 Electrochemical Measurements:  
All square wave voltammetric measurements were carried out using A CHI660 
potentiostat.  The electrochemical cell contained a glassy carbon electrode (GCE; 3.0 mm 
diameter, Model CHI104, CH Instruments, Austin, TX) as a working electrode, Ag/AgCl 
(sat. KCl) reference electrode (Model CHI111, CH Instruments, Austin,TX), and a 
platinum wire counter electrode were inserted into a 2 mL glass cell through holes in its 
Teflon cover. Before each Squarewave stripping voltammetry (SWSV) or cyclic 
voltammetry (CV) measurement, the GCE was polished with 3.0 and 0.05 μm alumina 
slurries and washed with doubly distilled water Each SWSV measurement was performed 
at room temperature in a quiescent 0.2 M KCl aqueous solution, and with an initial 
potential of 0.0 V and final potential of +1.6 V. 
3.4 UV-Vis and Kinetics Measurements: 
All kinetic measurements were made using a Carry UV-100 UV-Vis spectrophotometer. 
The Scanning Kinetic mode was used to investigate the change in electronic spectra for 
gold(III) complexes upon interaction with GSH and to determine the effective wave 
length for the reactions, then the kinetic mode was used to monitor the reaction progress 
at selected wavelength. A solution of 0.2 mM gold(III) complexes were prepared in water 
containing sodium chloride added to increase stability of mono- gold(III) complexes by 
prevent hydrolysis of chlorides [66], series of thiols solutions were also prepared, and 
equal volumes of  gold(III) complex solution and thiol solution were mixed and spectral 
changes were recorded using Scanning Kinetic mode in range from 250 nm to 350 nm. 
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Kinetic mode was used then to follow the reaction at three different temperatures. The 
collected data were plotted according to pseudo-first order kinetic equation (3.1) 
ln A = kobs.t + ln A◦                                                                               Eqn (3.1) 
Where: 
A◦: Initial Absorption 
A: Absorption at time t  
t: time in minute 
Pseudo-first order rate constant obtained from the slope value of the straight line 
correlation between kobs versus thiol concentration. 
kobs = k[Thiol]                                                                                        Eqn (3.2) 
 Using Microsoft -Excel, rate constants and activation parameters have been calculated 
from Eyring plots 
𝑙𝑛
k
𝑇
=  
−∆𝐻ǂ
𝑅
 
1
𝑇
+ 𝑙𝑛
𝑘𝐵
ℎ
+  
∆𝑆ǂ
𝑅
                                                     Eqn (3.3) 
Where: 
k: pseudo-first order rate constant  
R: universal gas constant 
T: absolute temperature 
kB: Poltzman constant 
Hǂ: enthalpy of activation 
Sǂ: entropy of activation 
The dependence of rate constant on Thiol concentration can be expressed as: 
k = kobs[Thiol]
n                                                                                        Eqn (3.4) 
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It can also be written as: 
ln k = log kobs + n ln[Thiol]                                                                  Eqn (3.5) 
The order of reaction (n) can be calculated using eqn(3.5) from plot of ln k versus ln 
[Thiol]. 
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CHAPTER 4  
Results and Discussion  
4.1 Interaction of 1,2-diamminocyclohexane gold(III) complexes with L-
Methionine: 
4.1.1 Interaction of [Au(cis-DACH)Cl2]Cl with L-Methionine: 
 
The interaction of gold(III) with biological ligands initiate an interest in these types of 
interactions with different important biological ligands such as amino acids and peptides, 
especially the interaction with sulphur containing amino acids, namely L-cysteine (L-
Cys) and L-Methionine (L-Met). These interactions are thought to be responsible for the 
toxic-side effects encountered in chrysotherapy such as nephrotoxicity. The interaction of 
L-Met with cis-diamminocyclohexane gold(III) chloride was studied by using NMR in 
acidic solution of pD 2.5 (correct according to isotope effect). The L-Met to reduce 
gold(III) to elemental gold at this pD of solution and the reaction involves oxidation of L-
Met by gold(III) to L-Methionine sulfoxide which is recognized as final product, the 
disappearance of methyl resonance in 13C NMR spectrum and at the same time observed 
resonance at about 37 ppm, assigned to methylsulfoxide resonance, is consider a strong 
indicator for formation of L-Methionine sulfoxide. In contrast appearance of free 
diamminecyclohexane as protonated ligands indicate redox of gold(III) to elemental 
gold(0) and loss of central metal ion. The reaction was monitored as function of L-Met 
ratio. The ration of gold(III) complex to L-Met was 1:2. The resonance of C1and C2 for 
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complex completely disappeared and the color of the solution was changed from yellow 
to colorless, and within this ratio the resonance of methyl at 14.5 ppm was obtained 
again. The 1H NMR showed the same behavior and the resonance of methyl protons 1.97 
ppm (3H, s) shifted downfield to 2.56 (3H, s). This is in agreement with 13C results. For 
more investigation L-Met was oxidized using H2O2 (30%) at pD of reaction then both 
1H 
and 13C resonance were recorded and the data gathered from this reactions was listed in 
(Tables 4.1 and 4.2 )  
Table 4. 1: 13C NMR Chemical shifts in ppm for L-Methionine and oxidized L-
Methionine in D2O pD 2.5. 
Position 13C δ in ppm for L-Met. , pD 2.5 13C δ in ppm for L-Met.+ H2O2 
30% , pD 2.5 
5 14.56 37.11 
4 29.93 48.67 
3 29.34 24.21 
2 53.51 53.27 
1 173.68 172.70 
   
Table 4. 2: 1H NMR δ in ppm for L-Methionine and oxidized L-Methionine in D2O pD 
2.5. 
Position 1H δ in ppm for 
L-Met.  pD 2.5 
Intensity Multiplicity 1H δ in ppm for 
L-Met.+ H2O2 
30% , pD 2.5 
Intensity Multiplicity 
5 1.97 3 s 2.56 3 s 
4 2.09 2 m 2.85 2 m 
3 2.51 2 t 2.18 2 t 
2 3.89 1 t 3.88 1 t 
             s: singlet, m: multiplet, t: triplet  
The suggested mechanism of reaction between [Au(cis-DACH)Cl2]Cl and L-Met can be 
driven as first of all L-Met coordinate to gold(III) through sulphur atom by substitution 
on one chlorido ligands forming [(Met-SAu(cis-DACH)Cl]2+ and this intermediate is 
subjected to further chlorido ligand substitution and formation of five membered ring 
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using nitrogen atom of amino group [Met-S,NAu(cis-DACH)]3+ this intermediate could 
produce Met-SO-CH3, which is identified by carbon resonance at 37 ppm along with 
resonance of protonated (DACH.H2)
2+ which identified by its corresponding resonance at 
50.55, 26.44 and 20.89 ppm. The resonance at 30.88 and 49.51 ppm were obtained at low 
concentration of L-Met (1:0.25 gold(III complex to L-Met) and completely disappeared 
by increasing L-Met concentration and were not observed in oxidized  L-Met solution 
that indicate these resonances are for L-Met-gold(III), the complete removal of DACH 
ligands from gold(III) complex was observed at 1:2 gold(III) complex to L-Met ligand 
similar study was conducted using [Au(en)Cl2]Cl [67], where the interaction with 
[AuCl4]
- was studied in details [62]. See Figure 4.1  
 
 
Figure 4. 1: 13C NMR for L-Met I) 10 mM L-Met in D2O II) after reaction with 10 mM 
[(cis-DACH)AuCl2]
+ (1:1)  III) after reaction with 20 mM [(cis-DACH)AuCl2]
+ (1:2) 
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4.1.2 Interaction of [Au(cis-DACH)2]Cl3 with L-Methionine: 
The interaction of L-Met with bis (cis-diamminocyclohexane)gold(III) was carried out 
using NMR as function of L-Met ratio and it shows less reactivity towards redox reaction 
compared with interaction with monodiamminocyclohexane complex, methysulfoxide 
resonance was also observed at about 37 ppm and complete removal of 
diamminocyclohexane ligand from bis complex occur when the ratio was raised to at 
molar ratio 1:2 in mono diammine complex that indicate relative stability of nitrogen 
tetracoordinted  gold(III) complexes and their ability to protect gold center from redox 
and also reflect the role of cis-di-chlorido ligands in mono diammine complex; which is 
suggested to be responsible by easy hydrolyzed and formation of di aqua complexes and 
the last one can easily by attacked by nucleophiles to exhibit reduction or substitution 
depending on ligand type and donar atom nature. All resonances were shown in (Figure 
4.2). 
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Figure 4.2:13C NMR for reaction of I) L-Met with II) one equivalent [Au(cis-
DACH)2]Cl3 III) 1:2 complex to L-Met at pD 2. 
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4.2 Interaction of [Au(cis-DACH)Cl2]Cl with DL-Selenomethionine: 
Because of their essential presence in mammals Selenium compounds have 
gained recently more attention [68]. The interaction between Se-Met and [Au(cis-
DACH)Cl2]Cl was carried out by mixing both compounds directly in D2O solution at 
different pD values, No change in spectram was obtained at pD 2 and 7 but when pD was 
raised to 12 using NaOD in D2O clear down-field shift for C5 from δ = 3.88 ppm to C5” 
35.6  ppm and C5’ 37.1 ppm corresponds to [(cis-DACH)Au(SeMet)]3+ and to oxidized 
CH3-SeO-Met respectively [69–71]. Signals were assigned by comparison with Se–Met 
oxidation experiment with hydrogen peroxide [72–74] this concomitant with reduction of 
gold(III) which  indicated by free cis-DACH resonance at 56.7 ppm  while 59.7 ppm 
could be assigned to  [(cis-DACH)Au(SeMet)]3+ which is shifted from 63 ppm in 
[Au(cis-DACH)Cl2]
+. 13C NMR spectra are shown in (Figure 4.3). 
The binding between gold(III) centre and Se-Met is in prospect to occur through 
the amine group or Selenium as indicated by Shoeib et al [75] in his computational study 
using methyl-seleno-cysteine.  
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Figure 4. 3: 13C NMR for reaction of SeMet, I) before reaction, II) with [Au(cis-
DACH)Cl2]
+ at pD 12. 
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4.3 Interaction of diamminocyclohexane gold(III) with glutathione: 
4.3.1 Interaction of [Au(cis-DACH)2]Cl3 with Glutathione: 
       In the NMR spectra (Fig 4.4) of 1:1 ratio of GSH with [Au(cis-DACH)Cl2]Cl, the 
C3 resonance (numbering according to (scheme 4.1) below ) was observed at 39 ppm 
instead of 27 ppm,  while the C2 resonance  showed an up-field shift that indicates GSH 
was oxidized to its corresponding disulfide  GSSG [76]. When the ratio reached 1:2,  the 
resonance,  C1 and C2 signals in [Au(cis-DACH)Cl2]Cl were shifted up-field toward the 
protonated (DACH.H2)
+2, implying loss of  Au(III) centre and  precipitation of polymeric 
gold(I) with GSSG from reaction mixture. Similar amount of GSH was oxidized in D2O 
at pD 2 using 30% H2O2 and 
13C NMR spectra for oxidized GSH shows similar shifts for 
GSSG obtained in reaction mixture, suggesting reaction mechanism for interaction of 
[Au(cis-DACH)Cl2]Cl with GSH as illustrated  in (scheme 4.2) 
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Scheme 4. 1: Glutathione 
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Scheme 4. 2: Proposed mechanism for interaction of [Au(cis-DACH)Cl2]Cl with GSH in 
acidic solution pD 2.5 
 
 
Figure 4. 4:13C NMR for I) 10 mM GSH in D2O II) after reaction with 10mM [(cis-
DACH)AuCl2]
+ (1:1)  III) 20 mM GSH with 10 mM [(cis-DACH)AuCl2]
+  (1:2). 
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4.3.2 UV-Vis and Kinetic measurements for interaction of glutathione with 
[Au(cis-DACH)Cl2]Cl, [Au(en)Cl2]Cl and [Au(en)2]Cl3: 
Scanning kinetics mode was used to record the electronic spectral change for reaction 
between glutathione with [Au(cis-DACH)Cl2]Cl, [Au(en)Cl2]Cl and [Au(en)2]Cl3, 0.2 
mM gold(III) diamine complexes were prepared in aqueous solution contain 40 mM 
sodium chloride to avoid hydrolysis of mono-gold(III) diammines chlorides. This was 
found not effective in case of bis-gold(III) complexes. Glutathione was prepared in water 
by mixing equal volumes of gold(III) complexes solutions and GSH solution inside 
measuring cell and electronic scanning kinetics spectra for all complexes showed 
appearance of an increasing absorption band at 297 nm at 298 K,  where the solution of 
0.2 mM [Au(cis-DACH)2]Cl3 with 1mM GSH solution shows another absorption band at 
240 nm. These absorption bands are assigned to formation of intermediates with general 
formulas  [Au(diamine)(SG)2]
+ and [Au(diamine)(SG)X]+ respectively. At higher 
concentration of GSH only absorption band at 297 nm corresponds  to  
[Au(diamine)(SG)2]
+ was observed, which  indicates that this intermediate is more stable 
than [Au(diamine)(SG)X]+. Scanning kinetics spectra for 0.2 mM gold(III) complexes 
with 2 mM GSH solution at 298 K are shown in (Figure 4.5).  
The kinetics of substitution reaction between potential anticancer gold(III) complexes 
[Au(cis-DACH)Cl2]Cl, [Au(en)2Cl2]Cl and [Au(en)2]Cl3 with glutathione was 
investigated spectrophotometrically by monitoring the spectral change of gold(III) 
complexes solution with excess of GSH. Equal volumes from gold(III) complexes and 
GSH were kept till it thermally equilibrate and then mixed directly inside a UV cell and 
the change in absorption at selected wavelength (297 nm) under pseudo-first order 
condition as function of GSH concentration and temperature was collected. Each  kinetic 
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measurement was repeated three times, kobs under this experiment conditions was 
determined using the mentioned Eqn (3.1) and the pseudo-first order rate constant was 
obtained from linear dependence of kobs vs total GSH concentration Eqn (3.2). NaCl was 
added in excess concentration. 
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Figure 4. 5: Scanning kinetics spectra for reaction of GSH with a) [Au(en)Cl2]Cl b) 
[Au(cis-DACH)Cl2]Cl c) I) GSH II) [Au(cis-DACH)2]Cl III) 0.2 mM complex to 2 mM 
GSH. 
 
Table 4. 3: Kinetic data for reaction of gold(III) diammines complexes with Glutathione. 
GSH ak  
M-1. s-1 
∆Hǂ 
 kJ. mol-1 
∆Sǂ 
 JK-1mol-1 
Ea 
 kJ.mol-1 
[Au(en)Cl2]+ (217 + 3) x10-2 18 + 0.9 -170 + 3 21  + 0.6 
[Au(en)2]3+ (103 + 8) x 10-2 11 + 1 -168 + 4 13 + 1.7 
[Au(cis-DACH)Cl2]+ (46 + 2) x10-2 37 + 0.8 -120 + 3 40  + 0.8 
[Au(cis-DACH)2]3+ (19 + 1) x 10-2 - - - 
Reaction carried out in aqueous solution in presence of 20mM NaCl for [Au(NN)Cl2]
+ 
complexes. a pseudo-first order rate constant at 298K. 
 
From the data given in Table (4.3), the values of rate constants and calculated activation 
parameters (∆Hǂ, ∆Sǂ and Ea) indicate that gold(III) complexes react differently from each 
other with GSH due to several factors. It can be seen that [Au(NN)Cl2]
+ reacts faster than 
[Au(NNNN)]3+ and this difference in reactivity can be attributed to ease of Chloride 
substitution by Sulphur ligands in [Au(NN)Cl2]
+ to form short life time intermediate 
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[Au(NN)(SG)2]
+ at 297 nm, however formation of this intermediate was not observed in 
NMR. DACH geometry also plays a very important role in term of reactivity of gold(III) 
centre as the chair conformation for DACH in its gold(III) complexes increase the 
stability by hindering GSH attack.  Such an effect is not offered by en ligand, due to its 
small size, and the rate constant increases by a factor of 8. There is also a small 
contribution in DACH gold(III) complexes due to the decrease in the electrophilicity of 
metal centre due to cyclohexane donation. The negative entropy of activation indicate 
that the entropy of transition state is too low compared with reactant entropy and that can 
be rationalized decrease in number of molecules by of the formation of the intermediate, 
where two bulky GSH molecules are tied to the complexes, thereby reducing the entropy. 
The order of substitution reaction between prepared square planar gold(III) complexes 
and GSH was determined by value of slope(n) from plot of ln k vs ln[GSH] (Eqn(3.5)). 
At all measured temperatures and the reaction obeys pseudo-first order kinetic. 
4.3.3 Electrochemical study of [Au(en)Cl2]Cl interaction with glutathione:  
Cyclic voltammograms were obtained for 1mM [Au(en)Cl2]Cl in HEPES buffer (25 mM, 
pH 7.4) in presence of 40mM NaCl at a GCE, Figure 4.6 shows well defined (CV) signal 
for 1 mM solution of  [Au(en)Cl2]Cl in presence of HEPES buffer at about 0.940 V (Vs 
Ag/AgCl sat KCl ) and this signal has subsequently shifted to 0.975 V and 1.04 V upon 
addition of 50 μM GSH solution, that indicate some interaction between GSH and 
gold(III) complex takes place, same fact was presented by SWSV for the mentioned 
gold(III) complex solution under the same experiment condition. 1mM [Au(en)Cl2]Cl in 
HEPES buffer is used, SWSV signal at around +0.875V (Vs Ag/AgCl sat KCl ) was 
observed as shown in Figure 4.7. Subsequent addition of 50 μM GSH to gold(III) 
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complex reduced the obtained complex signal towards the blank signal, control 
experiment was conducted by subsequent addition of 50 μM water to gold complex and 
collecting obtained SWSV signal. There was no reduction in complex signal that can be 
taken as a strong evidence to correlate the reduction of complex signal with glutathione 
interaction. 
 
 
Figure 4. 6: Cyclic voltammograms in HEPES buffer (25 mM, pH 7.4) at a GCE in 
absence (a) and presence (b) of 1.0 mM [Au(en)Cl2]Cl, and subsequent additions of 50 
µM GSH aqueous solution (c, d). Electrochemistry working conditions: scan rate, 100 
mVs-1; sample intervals 1 
 
Potential / V 
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Figure 4. 7: Square wave voltammograms in HEPES buffer (25 mM, pH 7.4) at a GCE in 
absence (a) and presence (b) of 1.0 mM [Au(en)Cl2]Cl, and subsequent additions of 50 
µM GSH aqueous solution (c-h). Electrochemistry working conditions: pulse width 
(increment), 4 mV; 
 
Table 4. 4: Observed rate constant for reaction of [Au(en)Cl2]
+ with GSH as a function of 
ligand concentration and temperature in presence of 20 mM NaCl at 297 nm. 
T/K 10-3CL/M kobs/min 
288.0 1 0.0717 
 2 0.1430 
 3 0.2546 
 4 0.3760 
 5 0.4806 
 6 0.5620 
298.0 1 0.0917 
 2 0.2469 
 3 0.4169 
 4 0.5047 
 5 0.6475 
 6 0.7496 
307.5 1 0.2902 
 2 0.4760 
 3 0.6275 
 4 0.8275 
 5 0.9976 
 6 1.181 
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Figure 4. 8: Pseudo-first order rate constant for reaction of [Au(en)Cl2]
+ with GSH as a 
function in ligand concentration and temperature in presence of 20 mM NaCl. 
 
Table 4. 5: Observed rate constant for reaction of [Au(en)2]
3+  with GSH as function of 
ligand concentration and temperature at 297 nm. 
T/K 10-3CL/M kobs/min 
288 1 0.0267 
 2 0.0670 
 3 0.1430 
 4 0.1417 
 5 0.2232 
 6 0.2823 
298 1 0.0338 
 2 0.1015 
 3 0.1941 
 4 0.2405 
 5 0.2699 
 6 0.3578 
310 1 0.0523 
 2 0.1768 
 3 0.2516 
 4 0.3153 
 5 0.3708 
 6 0.4463 
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Figure 4. 9: Pseudo-first order rate constant for reaction of [Au(en)2]
3+ with GSH as a 
function in ligand concentration and temperature. 
Table 4. 6: Observed rate constant for reaction of [Au(cis-DACH)Cl2]
+ with GSH as a 
function of ligand concentration and temperature in presence of  20 mM sodium chloride 
at 297 nm. 
T/K 10-3CL/M kobs /min 
288 1 0.0152 
 2 0.0440 
 3 0.0625 
 4 0.0722 
 5 0.0868 
298 1 0.0209 
 2 0.0497 
 3 0.0864 
 4 0.1097 
 5 0.1339 
303 1 0.0389 
 2 0.0851 
 3 0.1246 
 4 0.1408 
 5 0.2059 
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Figure 4. 10: Pseudo-first order rate constant for reaction of [Au(cis-DACH)Cl2]
+ with 
GSH as a function of  ligand concentration and temperature in presence of 20 mM NaCl. 
 
The order of substitution reaction between prepared square planar gold(III) complexes 
and GSH was determined by value of slope(n) from plot of ln k vs ln[GSH] (Eqn(3.5) 
Figs 4.11) at all measured temperatures, and the reaction obeys pseudo-first order kinetic.  
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Figure 4. 11: Plots of lnk vs ln[GSH] for GSH for (a) [Au(en)Cl2]Cl (b) [Au(cis-
DACH)Cl2]Cl (c) [Au(en)2]Cl3 
 
The reaction of GSH with potential anticancer gold(III) complexes based on diamines 
ligands was found to follow pseudo-first order kinetics under the experiment condition, 
y = 1.2x + 5.5
y = 1.2x + 5.8
y = 0.8x + 4.1
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
-7.5 -7.0 -6.5 -6.0 -5.5 -5.0
ln
 k
ln C
(a)
288 K
298 K
307.5 K
y = 1.1x + 3.3
y = 1.1x + 4.0
y = 1.0x + 3.6
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-7.5 -7.0 -6.5 -6.0 -5.5 -5.0
ln
 k
ln C
(b)
288 K
298 K
303 K
y = 1.2x + 5.3
y = 1.2x + 5.4
y = 1.1x + 5.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
-7.5 -7.0 -6.5 -6.0 -5.5 -5.0 -4.5
ln
 k
ln C
(c)
288 K
298 K
310 K
44 
 
and pseudo-first order rate constant explains substantial fact  that the selection of  ligand 
is very important issue not only in order to improve cytotoxicity of gold(III) complexes 
but also to increase stability of gold(III) complexes towards biological molecules and 
limits toxic side effects which results from loss of gold(III) centre and formation of 
elemental gold(0). The reactivity of examined gold(III) complexes towards GSH can be 
ranked as follow [Au(en)Cl2]Cl > [Au(en)2]Cl3 > [Au(DACH)Cl2]Cl > [Au(DACH)2]Cl3. 
NMR data shows formation of GSSG as final product beside free ligand at molar ratio 
1:2 that means reduction of gold(III) by GSH require 2 equivalents and there is no  
intermediate observed. The UV-VIS spectroscopy showed the presence of intermediate 
with formula [(NN)2Au(SG)2]
+ and pseudo-first rate constant for formation of this 
intermediate from [Au(en)Cl2]Cl, [Au(en)2]Cl3, [Au(DACH)Cl2]Cl and  
[Au(DACH)2]Cl3 is listed in Table 4.3. 
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4.4 Interaction of diamminocyclohexane gold(III) with imidazole: 
Imidazole (1,3-diaza-2,4-cyclopentadiene) is planar hetrocyclic compound consists of 
three carbon atoms and two nitrogen atoms (five membered ring)  in order 1,3 that is the 
source for systematic name 1,3-diazole, the resonance structure shows one of nitrogen 
atoms is forming sp2 and its lone pair is responsible for basic characteristics of imidazole 
[77]. This nitrogen represents an active site for many important biomolecules like amino 
acid L-His. Imidazole and its derivatives have broad domain in pharmacological 
applications as cardiovascular activity [78], analgesic and anti-inflammatory [79], anti-
neoplastic agents [80], anti- fungal agents [80] and enzyme inhibitor [81].  
4.4.1 Interaction of [Au(cis-DACH)Cl2]Cl with imidazole: 
The interaction between potential anticancer gold(III) complex of 1,2-
diaminocyclohexane [Au(cis-DACH)Cl2]Cl was carried out in 10 mM 
gold(III)complexes in D2O at  pD 7 by observing the shifts in 
1H and 13C NMR 
resonance. NMR spectra for reaction of [Au(cis-DACH)Cl2]Cl and Imidazole (1:1) 
showed up field shift in carbon resonance of C1and C2 of gold(III) complex from 63 ppm 
to 61 ppm along with increase in intensity of peak upon addition of another equivalent 
from Imidazole to reaction mixture and decrease in complex peak intensity concomitant 
with up-field shift of C1 for Imidazole from 136.2 ppm to 126.5 ppm which indicates 
binding through  nitrogen atom with similar up-field shift observed in Imidazole Carbons 
(Figure 4.13) . 1H resonance showed an increase in resonances 7.0 -8.3 ppm due to loss of 
molecule symmetry upon coordination to gold(III) and the final compound thought to 
have the formula [(cis-DACH)Au(Imi)2]
3+ (Figure 4.12) 
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Figure 4. 12: [(cis-DACH)Au(Imi)2]
3+ 
 
Figure 4. 13: 13CNMR for reaction of Imidazole with [Au(cis-DACH)Cl2]Cl in D2O at 
pD 7.4 I) 10 mM Imidazole before reaction II) with 10 mM [Au(cis-DACH)Cl2]Cl III) at 
20 mM Imidazole. 
 
4.4.2 Interaction of [Au(cis-DACH)2]Cl3 with imidazole:  
Potential anticancer gold(III) complex of cis-1,2-diaminoyclohexane [Au(cis-DACH)2]
3+ 
was prepared in 10 mM solution using D2O as solvent and amount of Imidazole 
equivalent to 10 mM was added. The pD of solution was adjusted at 7.3 then 1H and 13C 
NMR spectra were collected at prescribed reaction conditions and the results showed 
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there is no interaction between gold(III) complex and imidazole takes place, since all 13C 
resonance for  both gold(III) complex and Imidazole were obtained without any shifts 
(Figure 4.14).  
 
Figure 4. 14:13CNMR for reaction of Imidazole with [Au(cis-DACH)2]Cl3 in D2O at pD 
7.4 I) 10 mM Imidazole before reaction II) with 10 mM [Au(cis-DACH)2]Cl3. 
 
4.4.3 UV-Vis study of [Au(cis-DACH)Cl2]Cl interaction with imidazole:  
An aqueous solution of [Au(cis-DACH)Cl2]Cl was prepared in presence of 40 mM 
sodium chloride, electronic spectra was recorded for prepared solution absorption band 
was obtained at 305 nm with extension coefficient  2500 M-1cm-1 assigned to MLCT from 
gold centre to Chloride ligands as compared with Auric acid then equal volumes from 
gold(III) complex solution and imidazole were mixed inside UV cell and electronic 
spectrum was collected again, the absorption band for gold(III) complexes completely 
disappeared (Figure 4.15) this can be easily explained as removal of chlorides ligands 
from gold(III) and replaced by Imidazole ligands and that is in agreement with NMR 
data.  
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Figure 4. 15: Electronic spectra for reaction of [Au(cis-DACH)Cl2]
+ with Imidazole: a) 
before reaction b-e): after addition of Imidazole solution. 
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4.5 Interaction of 1, 2-diammino-gold(III) with DL-Penicillamine: 
Penicillamine is one of the chelator agents that have been used in pharmacology to 
remove heavy metals from body [82], It was used to treat Wilson’s disease [83]. It is 
Penicillin metabolites although it has no antibiotic activity, Pritchard et al. showed the 
importance of Penicillamine interaction with gold in treatment of rheumatoid disease 
[84]. 
SH
3
4
4'
2
NH2
1
O
OH 
Figure 4. 16: Structure of  Penicillamine 
4.5.1 Interaction of [Au(cis-DACH)Cl2]Cl with DL-Penicillamine: 
The interaction of DL-Penicillamine with gold(III) diammine ligand complexes was 
studied in details using multi-nuclear NMR and UV-Vis spectrophotometer ,  1H and 13C 
NMR spectra for DL-Penicillamine were obtained prior to  mixing with gold(III) 
complex and listed in (Table 4.7), the shifts in resonance values were then monitored.    
Table 4. 7: 13C NMR for PSH and oxidized PSH. 
 C1 C2 C3 C4, C4’ 
PSH 170.5 63.7 44.2 30.5, 28.4 
PSH + H2O2 (30%) 172.0, 171.6 65.3,62.6 50.7,50.6 30.9, 28.4, 27.4, 23.3 
[(cis-DACH)Au(SNP)]2+ 181.6 75.8 57.8 27.8, 26.5 
 
A solution of 10 mM [Au(cis-DACH)Cl2]Cl was prepared by dissolve 8.35mg gold(III) 
complex in 2mL D2O and amount of 3.00 mg DL-Penicillamine was added to prepared 
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solution (1:1) ratio, solution pD was adjusted to  3.8, then NMR spectra was collected. 
DL-Penicillamine was oxidized in D2O solution using H2O2 (30%) in order to investigate 
its disulfide resonances (Table 4.7 above), The appearance of the resonances at ~50.5, 
27.19 and 23.4 ppm in 13C NMR spectrum for reaction mixture could be taken as an 
evidence for oxidation of DL-PSH to its corresponds disulfide which indicates that it 
where [Au(cis-DACH)Cl2]
+ have been reduced to gold(I) and after few days white 
precipitate for gold(I)-PSSP was observed.  When gold(III) complex and PSH were 
mixed (1:1) the carbonyl resonance was obtained with down-field shift at 181.62 ppm 
followed by resonances at 75.76  ppm and 57.76 ppm  which corresponds to DL-
Penicillamine-C3and C3 in chelation intermediate [(cis-DACH)Au(SNP)2]
+. 
 
Figure 4. 17: 13C NMR for reaction of  I) 10 mM [Au(cis-DACH)Cl2]
+ with II) 10 mM 
PSH III) 20 mM PSH. 
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4.5.2 UV-Vis and Kinetics Measurements of [Au(en)Cl2]Cl and [Au(en)2]Cl3 
with DL-Penicillamine: 
The  Kinetics scan spectra obtained from monitoring mixture of solution of 0.5 mM 
gold(III)ethylenediamine complex with 0.5 mM DL-Penicillamine solution as time 
dependent (Figure 4.18) showed absorption band at about  233 nm, while solution of 0.5 
mM gold(III) ethylenediamine complex to 1 mM DL-Penicillamine solution as time 
dependent (Figure 4.19) showed an increased absorption band with time at 297 nm with 
rapid disappearance of band at 233 nm here based on this observation the reaction 
between gold(III) diamine complexs  can be summarized as DL-Penicillamine exchange 
one chloride ligand and form intermediate [Au(en)(SP)Cl]+ followed by further ligand 
exchange to form [Au(en)(SP)2]
+ this intermediate dissociate to give Penicillamine 
disulfide with reduction of gold(III) to gold(I) as observed in NMR . 
 
Figure 4. 18: Kinetics scan spectra for reaction of 0.5 mM [Au(en)Cl2]
+ with 0.5 mM DL-
Penicillamine in presence of 20 mM NaCl. 
 
[Au(en)(SP)Cl]+ 
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Figure 4. 19: Kinetics scan spectra for reaction of 0.5 mM [Au(en)Cl2]
+ with 2 mM PSH 
in presence of 20 mM NaCl. 
These intermediates were found to be stable under this low concentration over 48 hours 
where mixtures solution were kept for 48 hours and their electronic spectra were 
collected, absorption band at 234 nm was obtained from 1:1 mixture while absorption 
band at 297 nm was obtained from 1:2 mixture as shown in (Figure 4.20) 
 
Figure 4. 20: Reaction mixtures after 48 hours a) 0.5 mM : 0.5mM b) 0.5 mM: 2mM 
 
[Au(en)(SP)Cl]+ 
[Au(en)(SP)2]
+ 
b 
a 
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 Kinetic measurements were performed at pseudo-first order condition as 
function of ligand concentration at 297 nm as working wavelength. Each kinetic 
measurement was repeated three times; then pseudo-first order rate constant was 
calculated using Eqn (3.1). Each reaction was evaluated at three different temperatures 
288K, 298K and 310K, and obtained date were plotted using eyring and Arrhenius 
activation parameters were calculated and listed in (Table 4.8) 
Table 4. 8: Kinetic data for reaction of PSH with 1) [Au(en)Cl2]
+ 2) [Au(en)2]
3+ 
PSH k obs / M
-1. s-1 ∆Hǂ  
kJ . mol-1 
∆Sǂ  
JK-1mol-1 
Ea 
 kJ . mol-1 288K 298K 310K 
1 (95+2)x10-2 (109+2)x10-2 (103+4)x10-2 8.0 + 0.3 -210 + 1 11 + 0.3 
2 (135+5)x10-2 (217+6)x10-2 (260+5)x10-2 17 + 3 -175 + 12 22 + 1 
 
Figure 4. 21: Scanning kinetics spectra for reaction of PSH with [Au(en)2]
3+ at 298 K. 
 
 
 
 
[Au(en)(SP)N]2+ 
[Au(en)(SP)2]
+ 
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Table 4. 9: Observed rate constant for reaction of [Au(en)Cl2]
+ with PSH as a function of 
ligand concentration in presence of 20 mM sodium chloride at 297 nm. 
T/K 10-3CL/M kobs/min 
288 1 0.1488 
 2 0.2251 
 3 0.2889 
 4 0.3371 
 5 0.3953 
 6 0.4344 
298 1 0.2313 
 2 0.3029 
 3 0.3638 
 4 0.4217 
 5 0.4914 
 6 0.5591 
310 1 0.3379 
 2 0.4464 
 3 0.5105 
 4 0.5887 
 5 0.6681 
 6 0.7352 
 
 
Figure 4. 22: Observed rate constant for reaction of [Au(en)Cl2]
+ with PSH as a function 
of ligand concentration  in presence of 20 mM sodium chloride 
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Table 4. 10: Observed rate constant for reaction of [Au(en)2]
3+ with PSH as function of 
ligand concentration in presence of 20mM sodium chloride at 297 nm. 
T/K 10-3CL/M kobs/min 
288 1 0.2360 
 2 0.3233 
 3 0.4446 
 4 0.4961 
 5 0.5574 
298 1 0.3434 
 2 0.5244 
   3 0.6290 
   4 0.7569 
 5 0.8727 
310 1 0.6042 
 2 0.7418 
 3 0.8883 
 4 1.0668 
 5 1.2219 
 
 
Figure 4. 23: Observed rate constant for reaction of [Au(en)2]
3+ with PSH  as a function 
of ligand concentration in presence of 20 mM sodium chloride. 
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4.5.3 UV-Vis and Kinetics Measurements of [Au(cis-DACH)Cl2]Cl and 
[Au(cis-DACH)2]Cl3 with DL-Penicillamine: 
Electronic spectra for reaction mixture of [Au(cis-DACH)Cl2]Cl and [Au(cis-
DACH)2]Cl3 0.2 mM with 2 mM DL-Penicillamine in their aqueous solutions containing 
20 mM sodium chloride  gave the same absorption bands which are at 233 nm and 297 
nm,  and the absorption band at 233 nm  rapidly disappeared with time and absorption 
band at 297 nm. These absorptions thought to be sulfur to gold(III) CT (Figure 4.24) and 
this is  consider as strong evidence for formation of  intermediates with formulas [Au(cis-
DACH)(SP)X]+ and [Au(cis-DACH)(SP)2]
+ respectively.  That explains the reduction of 
[Au(cis-DACH)Cl2]Cl which occurs through two consecutive steps. First step is 
substitution of one chloride ligand by Penicillamine ligand followed by further ligand 
substitution then reductive elimination to produce gold(I) with Penicillamine oxidized to 
Penicillamine disulfide.   
 
Figure 4. 24:Scanning kinetics spectra for reaction of PSH with [Au(cis-DACH)Cl2]
+ in 
presence of 20 mM NaCl. 
[Au(cis-DACH)(SP)Cl]+ 
[Au(cis-DACH)(SP)2]
+ 
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Figure 4. 25: Scanning kinetics spectra for reaction of PSH with [Au(cis-DACH)2]
3+ in 
presence of 20 mM NaCl. 
Scanning kinetics mode was employed to monitor the reaction progress, equal volumes 
from gold(III) cis-diamonocyclohexane complexes and DL-Penicillamine  were kept till 
it were thermally stable then mixed directly inside UV cell at 297 nm. The reaction 
progress obtained as time dependant, each concentration was repeated three times and 
reaction was conducted at three different temperatures 288K, 298K and 310K. Data was 
treated using mentioned Eqns (3.1-5) pseudo-first order rate constants (k), entropy of 
activation (∆Sǂ) enthalpy of activation (∆Hǂ) and activation energy E were calculated and 
all kinetics data were listed in Table (4.11) below. 
Table 4. 11: Kinetics data for reaction of PSH with 1) [Au(cis-DACH)Cl2]
+ 2) [Au(cis-
DACH)2]
3+ 
PSH k M-1. s-1 ∆Hǂ 
 kJ . mol-1 
∆Sǂ 
 JK-1mol-1 
Ea  
kJ. mol-1 288K 298K 310K 
1 (43+2)x10-2 (68+0.8)x10-2 (136+2)x10-2 36 + 1 -120 + 3  38 + 1 
2 (101+3)x10-2 (172+3) x10-2 (221+0)x10-2 24 + 1 -155 + 3 26 + 1 
[Au(cis-DACH)(SP)N]2+ 
[Au(cis-DACH)(SP)2]
 + 
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Table 4. 12:  Observed rate constant for reaction of [Au(cis-DACH)Cl2]
+ with PSH as a 
function of ligand concentration in presence of 20 mM sodium chloride at 297 nm. 
T/K 10-3CL/M kobs/min 
288 1 0.0402 
 2 0.0665 
 3 0.1013 
 4 0.1211 
 5 0.1404 
 6 0.1734 
298 1 0.0710 
 2 0.1222 
 3 0.1647 
 4 0.2007 
 5 0.2417 
 6 0.2807 
310 1 0.1251 
 2 0.1924 
 3 0.2873 
 4 0.3543 
 5 0.4657 
 6 0.5202 
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Figure 4. 26: Observed rate constant for reaction of [Au(cis-DACH)Cl2]
+ with PSH as a 
function of PSH concentration and temperature in presence of 20 mM sodium chloride. 
Table 4. 13: Observed rate constant for reaction of [Au(cis-DACH)2]
3+ with PSH as a 
function in ligand concentration in presence of 20 mM sodium chloride at 297 nm. 
T/K 10-3CL/M k obs/min 
288 1 0.2240 
 2 0.2882 
 3 0.3634 
 4 0.4050 
 5 0.4686 
298 1 0.4571 
 2 0.5401 
  3 0.6501 
  4 0.7430 
 5 0.8705 
310 1 0.5849 
 2 0.7323 
 3 0.8334 
 4 0.9876 
 5 - 
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Figure 4. 27: Observed rate constant for reaction of PSH with [Au(cis-DACH)2]
3+ as a 
function of PSH concentration and temperature.  
4.6 Interaction of diamminegold(III) complexes with Thiomalic acid: 
4.6.1 Interaction of [Au(cis-DACH)Cl2]Cl complexes with Thiomalic acid: 
Thiomalic acid (TmSH) complexes with gold are used  fundamentally in treatment of  
rheumatoid arthritis because of  their anti-inflammatory action [85]. Interaction of 
thiomalic acid with [Au(cis-DACH)Cl2]
+ was studied using NMR technique in D2O 
solution in acidic conditions. 
13C spectra for TmSH was recorded in D2O solution prior to mixing with [Au(cis-
DACH)Cl2]
+ and then it has been oxidized by 30% H2O2. C2 resonance shifted down-
field to C2’ at 47 ppm, when C3 was shifted up-field to C3’ at ~ 36 ppm. 13C NMR 
spectra for reaction of TmSH with [Au(cis-DACH)Cl2]
+ is shown in (Figure 4.28). 
similar down-field was observed for C2 while C3 also showed slight up-field shift that 
confirm oxidation of TmSH to disulfide along with gold(III) complexes reduction as 
indicated by resonance  at ~ 50 ppm which is assigned to C1 and C2 (indicated by Ca’) in 
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protonated DACH ligands. Complete disappearance for Ca resonance was obtained at 
reaction mixture 1:2 gold(III) complex to TmSH. 
 
Figure 4. 28: 13C NMR spectra for reaction of TmSH with [Au(cis-DACH)Cl2]Cl in 
acidic condition, I) TmSH before reaction II) after addition of one equivalent [Au(cis-
DACH)Cl2]Cl III) with two equivalents [Au(cis-DACH)Cl2]Cl. 
 
4.6.2 UV-Vis for gold (III) diamminocyclohexane complex with Thiomalic acid: 
Scanning kinetics mode was employed to investigate the spectral for reaction mixture 
between gold(III) complex and thiomalic acid, no change in electronic spectra for 
gold(III) complex solution was observed in low concentration with TmSH but when the 
ratio was raised to 1:10 (0.2 mM [Au(cis-DACH)Cl2]
+ in 40 mM NaCl solution to 2mM 
TmSH solution) and monitored to 20 min intense absorption band appeared in 297-300 
nm and went to disappear, this absorption band could be assigned to formation of 
Substitution intermediate for gold(III) complexes prior to reduction with two TmSH 
molecules [Au(cis-DACH)(Tm)2]
+ as shown in Figure 4.29.   
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Figure 4. 29: Scanning kinetics spectra for reaction of 0.2mM [Au(cis-DACH)Cl2]Cl 
with 2mM TmSH in presence of 20 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Au(cis-DACH)(Tm)2]
+ 
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4.7  Kinetics study of N-(2-Mercaptoprpinyl)gGlycine interaction  with 
diamminocyclohexane gold(III) complex:  
N-(2-Mercaptoprpinyl)glycine (MPG) interaction with potential anticancer gold(III) 
complex of [Au(cis-DACH)Cl2]Cl was investigated spectrophotometerically in terms of 
kinetics, pseudo-first order conditions were applied to study the reaction in aquoes 
solution in presence of 20 mM NaCl, scanning kinetics gave well defined absorption 
band at 297 nm assigned by comparison to [Au(cis-DACH)(MPG)2]
+ (Figure 4.30) 
bellow. 
 
Figure 4. 30: Scanning kinetic spectra for reaction of MPG with [Au(cis-DACH)Cl2]
+ 
 
It is clearly seen that the difference between each time dependant run is relatively large 
compared with previously investigated thiols (GSH and PSH) and after about 5 minutes 
there is no change in absorption. Furthermore rate of formation of this intermediate was 
calculated under ascribed condition with activation parameters (Table 4.14) 
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Table 4. 14: Kinetics data for reaction of MPG with [Au(cis-DACH)Cl2]
+ 
MPG k M-1. s-1 ∆Hǂ 
 kJ . mol-1 
∆Sǂ 
 JK-1mol-1 
Ea 
 kJ . mol-1  288 K 298 K 310 K 
[Au(DACH)Cl2]
+ 2.5 3.6 4.9 20 -163 22 
 
 
Figure 4. 31: Observed rate constant for reaction of MPG with [Au(cis-DACH)Cl2]
+ as a 
function of MPG concentration and temperature in presence of 20 mM sodium chloride.  
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4.8 Kinetics of [Au(cis-DACH)Cl2]Cl interaction with Mercaptoacetic 
acid : 
 
The interaction of [Au(cis-DACH)Cl2]Cl with Mercaptoacetic acid (MAA)was carried 
out using UV/Vis spectrophotometer, a solution of 0.2 mM  of [Au(cis-DACH)Cl2]Cl 
was prepared in presence of 40 mM NaCl. Series of MAA solution were also prepared 
then effective wavelength was determined as 298 nm using scanning kinetics mode at 
298K. 
Pseudo-first order rate constant was determined for the reaction of [Au(cis-DACH)Cl2]Cl 
with MAA under pseudo-first order conditions at three different temperatures 288K, 
298K and 310K, Arrhenius and Eyring equations were applied to calculate activation 
parameters ∆Hǂ, ∆Sǂ and  Ea and calculated values showed that MAA has the highest 
reactivity towards substitution reaction with [Au(cis-DACH)Cl2]Cl with correspondence 
pseudo-first order rate constant as 57 + 3 M-1s-1 at 298K.  All values were listed in (Table 
4.15) bellow  
Table 4. 15: Kinetics data for reaction of MAA with [Au(cis-DACH)Cl2]
+ 
MAA k M-1. s-1 ∆Hǂ  
kJ . mol-1 
∆Sǂ  
JK-1mol-1 
Ea  
kJ . mol-1  288K 298K 310K 
[Au(cis-DACH)Cl2]
+ 43 + 0.6 57 + 3 99 + 0.02 25 + 0.4 -117 + 1 28 + 0.4 
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Figure 4. 32: Observed rate constant for reaction of MAA with [Au(cis-DACH)Cl2]
+ as a 
function of MAA concentration and temperature in presence of 20 mM sodium chloride.  
 
The kinetic data for all studied reactions were listed in Table (4.16) bellow in comparison 
with some reaction for same gold(III)-DACH complex with biologically relevant 
molecules.  
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Table 4. 16: Kinetic data for reaction of gold(III) diammines complexes with different 
biological molecules in aqueous solution in presence of 20mM NaCl for [Au(NN)Cl2]
+ 
complexes. 
 ak 
M-1. s-1 
∆Hǂ  
kJ . mol-1 
∆Sǂ  
JK-1mol-1 
Ea 
 kJ . mol-1 
Reference 
 
[Au(DACH)Cl2]
+      
GSH  (46 + 2) x10-2 37.3 + 0.8 -120 + 3 40  + 0.8 This work 
PSH (68 + 1) x10-2 36 + 1 -120 + 3  38 + 1 This work 
Ino 9.9 + 0.9 - - - [66] 
5’-IMP 6.0 + 0.3 - - - [66] 
5’-GMP 66 + 2 10 + 3 -180 + 10 - [66] 
L-His 75 + 2 12 + 3 -160  + 10 - [66] 
KCN 148 39 -80 42 [86] 
MAA 57 + 3 25 + 0.4 -117 + 1 28 + 0.4 This work 
MPG 2.5 19.5 -162.6 22.0 This work 
[Au(en)Cl2]
+
      
GSH (217 + 3) x10
-2 18 + 0.9 -170 + 3 21  + 0.6 This work 
PSH (109 + 2) x10
-2 8.0 + 0.3 -210 + 1 11 + 0.3 This work 
L-His 39 + 3 - - - [59] 
[Au(en)2]
3+
      
GSH (103 + 8) x 10
-2 11 + 1 -168 + 4 13 + 1.7 This work 
PSH (217 + 6) x 10
-2 17 + 3 -175 + 12 22 + 1 This work 
[Au(DACH)2]
3+      
GSH (19 + 1) x 10-2 - - - This work 
PSH (172 + 3) x 10
-2 24 + 1.0 -155 + 3 26 + 1 This work 
KCN 18 11 -185 13 [86] 
                a Pseudo-first order rate constant at 298K.  
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Chapter 5 
Conclusions and Recommendations 
In this work we have studied the interaction of some potential anticancer gold(III) 
complexes of 1,2-diammine containing ligands with biologically important molecules 
like L-methionine, DL-selenomethionine, glutathione, imidazole, DL-penicillamine, 
thiomalic acid, mercaptoacetic acid and N-(2-mercaptopropinyl)glycine. Our results 
showed the reduction of gold(III) to gold(I) and gold(0) that occurs upon reaction 
with sulphur containing ligands, while nitrogen donar ligands have been substituted 
and coordinated to gold(III). 
Final product identification was based on comparison with oxidized ligands using 
H2O2 under the same reaction conditions. thioether and selenoether were oxidized to 
their corresponding sulfoxide and selenoxide; where thiols oxidation products were 
obtained as disulfides. The reactivity of studied gold(III) complexes to form 
diamminodithiolato gold(III) intermediate can be racked as: ethylenediamine gold(III) 
complexes are faster than diaminocyclohexane gold(III) complexes where mono 
diamino gold(III) complexes react faster than bis diamino gold(III) complexes. 
For future recommendations, more studies for gold(III) complexes interaction with 
biologically importance molecules will lead to better understanding for its 
cytotoxicity and it will help in developing and designing stable compounds with low 
toxicity. Interaction with nucleobases should be carried out using stopped-flow 
technique. 
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